期刊文献+

甲磺酸伊马替尼致三度房室传导阻滞 被引量:6

Atrioventricular block Ⅲ caused by imatinib mesylate
原文传递
导出
摘要 1例31岁男性患者因慢性粒细胞白血病口服甲磺酸伊马替尼400mg,1次/d。患者既往无心脏病、高血压病史。治疗前心电图和超声波检查示心功能正常。治疗第1天,患者出现心前区不适。第6天出现心律失常,三度房室传导阻滞,HR45次/min。停用甲磺酸伊马替尼,给予支持治疗,安装临时起博器,患者症状好转。 A 31-year-old man received oral imatinib mesylate 400 mg once daily for chronic granulocytic leukemia. The patient had no previous history of heart disease or hypertension. An ECG and ultrasound revealed normal cardiac function before treatment. On day 1 of therapy, he experienced precordial discomfort. On day 6, he developed arrhythmia and atrioventricular block Ⅲ, his heart rate was 45 beats/min. Imatinib mesylate was discontinued. He received supportive treatment and a temporary pacemaker. His symptoms improved.
出处 《药物不良反应杂志》 2009年第2期130-131,共2页 Adverse Drug Reactions Journal
关键词 甲磺酸伊马替尼 房室传导阻滞 不良反应 imatinib mesylate atrioventricular block adverse reactions
  • 相关文献

参考文献5

二级参考文献21

  • 1Safety Alert.United States Food and Drug Administration,19 October,2006.(http://www.fda.gov)
  • 2Cohen MH,Williams G,Johnson JR,et al.Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia[J].Clin Cancer Res.2002 May;8(5):935~42.
  • 3Dagher R,Cohen M,Williams G,et al.Approval summary:imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors[J].Clin Cancer Res.2002 Oct;8(10):3034~8.
  • 4Donato NJ,Wu JY,Stapley J,et al.Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia[J].Cancer Res,2004,64(2):672~677.
  • 5Gambacorti-Passerini C,Barni R,Ie Coutre P,et al.Role of alphal acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.J Natl Cancer Inst,2000,92(20:1641-50.
  • 6Gambacorti-Passerini C,Corneo G,D'Incalci M.Roots of clinical resistance to STI-571 cancer therapy.Science,2001,293(5538):2163.
  • 7Rumpold H,Wolf AM,Gruenewald K,et al.RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durable restores imatinib sensitivity in imatinib-resistant CML cell lines[J].Exp Hematol,2005,33(7):767~775.
  • 8Luzzatto L,Frassoni F,Melo JV.Imatinib:can one outwit chronic myeloid leukemia?[J].Haematologica,2002,(9):898-901.
  • 9Weisberg E,Manley P,Mestan J,et al.AMN107 (nilotinib):a novel and selective inhibitor of BCR-ABL[J].Br J Cancer,2006,May 23.
  • 10Mohi MG,Boulton C,Gu TI,et al.Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs[J].Proc Natl Acad Sci USA,2004,101(9):3130~3135.

共引文献13

同被引文献94

引证文献6

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部